Scientists Pinpoint a Hidden Driver of Alzheimer's — and a Compound That Slows It in Mice

Alzheimer's disease has long been framed as a story about amyloid beta, the sticky protein that clumps into plaques between brain cells. But researchers at ETH Zurich say they have identified a different culprit lurking deeper in the machinery of the neuron — and a compound that appears to rein it in. The findings, the product of nearly two decades of work, point to a fresh target for a disease that has frustrated drug developers for a generation.

At the center of the discovery is a protein called GRK2. In the brains of affected animals, the researchers found, dysfunctional GRK2 accumulates around mitochondria, the tiny structures that supply cells with energy. That buildup appears to choke the neuron's power supply, setting off a cascade of damage that contributes to the cognitive decline seen in dementia. The work was led by Ursula Quitterer, a professor of molecular pharmacology, whose team spent years assembling the evidence linking GRK2 to the disease.

To test whether the process could be interrupted, the team turned to a chemical they developed and call Compound 10. In treated animals, the results were encouraging on several fronts at once: mitochondria functioned more effectively, less amyloid beta accumulated, and nerve cells stayed healthy and operational. The compound slowed the progression of dementia-like symptoms — and, intriguingly, showed signs of anti-aging effects elsewhere in the body.

The research, published in the journal Cell Reports Medicine, is a long way from a pill on a pharmacy shelf. The work was conducted in animal models, and the long, expensive road of human clinical trials lies ahead, where countless promising Alzheimer's candidates have foundered before. Still, the dual action — protecting the cellular energy supply while also curbing amyloid — gives the approach a mechanistic appeal that pure plaque-clearing therapies have lacked.

The emphasis on mitochondria fits a growing body of research suggesting that failures in cellular energy production are not merely a side effect of Alzheimer's but may help drive it. Neurons are among the most energy-hungry cells in the body, and when their power plants falter, the consequences ripple outward — impairing the cellular housekeeping that normally clears toxic proteins and keeps synapses firing. A therapy that protects those power plants could, in principle, address the disease closer to its roots.

For a field battered by repeated failures and only a handful of modestly effective drugs, a genuinely new target is significant in itself. By shifting attention from the plaques outside neurons to the energy crisis within them, the ETH Zurich work reframes part of the Alzheimer's puzzle — and offers a tangible lead for the next generation of treatments to chase.